Medistim ASA (LTS:0OCD) Cyclically Adjusted Revenue per Share: kr27.82 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0OCD Medistim ASA LTS:0OCD
100 GF Score
Price kr231.00
GF Value kr260.85
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medistim ASA Cyclically Adjusted Revenue per Share?

Medistim ASA LTS:0OCD 100 Cyclically Adjusted Revenue per Share is kr27.82 as of Mar. 2026. GuruFocus rates LTS:0OCD with a GF Score™ of 100/100 and a GF Value™ of kr260.85 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Medistim ASA's adjusted revenue per share for the three months ended in Mar. 2026 was kr11.027. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr27.82 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Medistim ASA's average Cyclically Adjusted Revenue Growth Rate was 11.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Medistim ASA was 13.00% per year. The lowest was 7.90% per year. And the median was 11.10% per year.

As of today (2026-07-17), Medistim ASA's current stock price is kr231.00. Medistim ASA's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr27.82. Medistim ASA's Cyclically Adjusted PS Ratio of today is 8.30.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medistim ASA was 23.03. The lowest was 4.75. And the median was 9.79.


Medistim ASA  (LTS:0OCD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medistim ASA's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=231.00/27.82
=8.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medistim ASA was 23.03. The lowest was 4.75. And the median was 9.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Medistim ASA Cyclically Adjusted Revenue per Share Related Terms


Medistim ASA Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Medistim ASA's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medistim ASA Cyclically Adjusted Revenue per Share Chart

Medistim ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.58 23.10 27.97 24.46 27.11

Medistim ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.40 26.09 26.90 27.11 27.82

LTS:0OCD vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Medistim ASA's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medistim ASA Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medistim ASA's Cyclically Adjusted PS Ratio falls into.


LTS:0OCD
100GF Score
Medistim ASA LTS:0OCD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medistim ASA Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medistim ASA's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=11.027/141.0300*141.0300
=11.027

Current CPI (Mar. 2026) = 141.0300.

Medistim ASA Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 3.709 103.800 5.039
201609 3.743 104.200 5.066
201612 3.419 104.400 4.619
201703 4.094 105.000 5.499
201706 3.809 105.800 5.077
201709 4.168 105.900 5.551
201712 4.230 106.100 5.623
201803 4.079 107.300 5.361
201806 4.193 108.500 5.450
201809 4.269 109.500 5.498
201812 5.187 109.800 6.662
201903 4.878 110.400 6.231
201906 5.157 110.600 6.576
201909 4.702 111.100 5.969
201912 4.885 111.300 6.190
202003 5.665 111.200 7.185
202006 4.535 112.100 5.705
202009 4.571 112.900 5.710
202012 4.785 112.900 5.977
202103 5.625 114.600 6.922
202106 6.016 115.300 7.359
202109 5.598 117.500 6.719
202112 5.657 118.900 6.710
202203 6.357 119.800 7.484
202206 6.430 122.600 7.397
202209 6.372 125.600 7.155
202212 7.447 125.900 8.342
202303 7.068 127.600 7.812
202306 7.512 130.400 8.124
202309 6.786 129.800 7.373
202312 7.407 131.900 7.920
202403 7.305 132.600 7.769
202406 7.913 133.800 8.341
202409 7.249 133.700 7.646
202412 8.253 134.800 8.634
202503 9.921 136.100 10.280
202506 9.263 137.800 9.480
202509 9.131 138.500 9.298
202512 9.975 139.100 10.113
202603 11.027 141.030 11.027

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr27.82 mean?
Medistim ASA (LTS:0OCD) has a Cyclically Adjusted Revenue per Share of kr27.82 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medistim ASA and its competitors.
Is Medistim ASA's Cyclically Adjusted Revenue per Share too high?
Medistim ASA's current Cyclically Adjusted Revenue per Share is kr27.82. Overall, Medistim ASA has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Medistim ASA's Cyclically Adjusted Revenue per Share of kr27.82 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medistim ASA and its competitors. Medistim ASA's current Cyclically Adjusted Revenue per Share is kr27.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (LTS:0OCD) is currently considered Modestly Undervalued. The stock's GF Value™ is kr260.85, compared to a current price of kr231.00 — trading 11.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr27.82. Medistim ASA's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Medistim ASA (LTS:0OCD), the current Cyclically Adjusted Revenue per Share is kr27.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medistim ASA (LTS:0OCD) Overvalued in 2026?

Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued. The current stock price of kr231.00 is trading 11.4% below its estimated GF Value™ of kr260.85. GuruFocus considers Medistim ASA to be Modestly Undervalued.

Key valuation signals for LTS:0OCD:

  • Cyclically Adjusted Revenue per Share: kr27.82
  • GF Value™: kr260.85 vs. price of kr231.00 (11.4% below fair value)
  • GF Score™: 100/100 with 1 warning sign

No single metric tells the full story. See the LTS:0OCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medistim ASA Business Description

Address Okernveien 94, Oslo, NOR, 0579
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
100GF Score

Get the complete analysis for LTS:0OCD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr231.00
Price
kr260.85
GF Value